Literature DB >> 4241814

Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors.

D Ogston, C M Ogston, O D Ratnoff, C D Forbes.   

Abstract

As demonstrated by others, fibrinolytic activity was generated in diluted, acidified normal plasma exposed to kaolin, a process requiring Hageman factor (Factor XII). Generation was impaired by adsorbing plasma with glass or similar agents under conditions which did not deplete its content of Hageman factor or plasminogen. The defect could be repaired by addition of a noneuglobulin fraction of plasma or an agent or agents eluted from diatomaceous earth which had been exposed to normal plasma. The restorative agent, tentatively called Hageman factor-cofactor, was partially purified by chromatography and had an apparent molecular weight of approximately 165,000. It could be distinguished from plasma thromboplastin antecedent (Factor XI) and plasma kallikrein, other substrates of Hageman factor, and from the streptokinase-activated pro-activator of plasminogen. Evidence is presented that an additional component may be needed for the generation of fibrinolytic activity in mixtures containing Hageman factor, HF-cofactor, and plasminogen.The long-recognized generation of plasmin activity in chloroform-treated euglobulin fractions of plasma was found to be dependent upon the presence of Hageman factor. Whether chloroform activation of plasminogen requires Hageman factor-cofactor was not determined, but glass-adsorbed plasma, containing Hageman factor and plasminogen, did not generate appreciable fibrinolytic or caseinolytic activity. These studies emphasize the complex nature of the mechanisms which lead to the generation of plasmin in human plasma.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4241814      PMCID: PMC322415          DOI: 10.1172/JCI106145

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  ACTIVATION OF HAGEMAN FACTOR BY SOLUTIONS OF ELLAGIC ACID.

Authors:  O D RATNOFF; J D CRUM
Journal:  J Lab Clin Med       Date:  1964-03

2.  HAGEMAN FACTOR IN THE FIBRINOLYTIC SYSTEM.

Authors:  J AZNAR; A LOPEZ-BORRASCA
Journal:  Lancet       Date:  1965-02-20       Impact factor: 79.321

3.  The purification of activated Hageman factor (activated factor XII).

Authors:  O D RATNOFF; E W DAVIE
Journal:  Biochemistry       Date:  1962-11       Impact factor: 3.162

4.  Induction of fibrinolysis by venous obstruction.

Authors:  R L CLARKE; A ORANDI; E E CLIFFTON
Journal:  Angiology       Date:  1960-10       Impact factor: 3.619

5.  Selective inactivation of the plasminogen contaminant in thrombin.

Authors:  G MARKUS; C M AMBRUS
Journal:  Nature       Date:  1960-11-12       Impact factor: 49.962

6.  Studies on the thrombolytic activity of human plasma.

Authors:  W D SAWYER; A P FLETCHER; N ALKJAERSIN; S SHERRY
Journal:  J Clin Invest       Date:  1960-02       Impact factor: 14.808

7.  A plasminogen activator in spontaneously active human blood.

Authors:  S MULLERTZ
Journal:  Proc Soc Exp Biol Med       Date:  1953-02

8.  Abolition of the permeability-enhancing properties of Hageman factor by specific antiserum.

Authors:  R W Kellermeyer; O D Ratnoff
Journal:  J Lab Clin Med       Date:  1967-09

9.  Immunologic demonstration of a deficiency of Hageman factor-like material in Hageman trait.

Authors:  M M Smink; T M Daniel; O D Ratnoff; A B Stavitsky
Journal:  J Lab Clin Med       Date:  1967-05

10.  The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor.

Authors:  O D Ratnoff; J Pensky; D Ogston; G B Naff
Journal:  J Exp Med       Date:  1969-02-01       Impact factor: 14.307

View more
  26 in total

1.  Partial purification and characterization of contact activation cofactor.

Authors:  S Schiffman; P Lee
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

Review 2.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

Review 3.  [The enzymatic linkage of fibrinogenesis and fibrinolysis (author's transl)].

Authors:  R E Zimmermann; J Lubinus
Journal:  Klin Wochenschr       Date:  1978-08-15

Review 4.  Streptokinase: a review of its clinical pharmacology, mechanism of action and therapeutic uses.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1973       Impact factor: 9.546

5.  Structural changes accompanying enzymatic activation of human Hageman factor.

Authors:  S D Revak; C G Cochrane; A R Johnston; T E Hugli
Journal:  J Clin Invest       Date:  1974-09       Impact factor: 14.808

Review 6.  Anticoagulant and thrombolytic drugs. I. Patho-physiological and pharmacological aspects.

Authors:  D Ogston; A S Douglas
Journal:  Drugs       Date:  1971       Impact factor: 9.546

7.  Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation.

Authors:  A D Schreiber; A P Kaplan; K F Austen
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

8.  Clinical experience with brinase.

Authors:  E P Frisch
Journal:  J Clin Pathol       Date:  1972-07       Impact factor: 3.411

9.  Separation of plasma thromboplastin antecedent from kallikrein by the plasma 2 -macroglobulin, kallikrein inhibitor.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1971-10       Impact factor: 14.808

10.  Partial purification of plasma thromboplastin antecedent (factor XI) and its activation by trypsin.

Authors:  H Saito; O D Ratnoff; J S Marshall; J Pensky
Journal:  J Clin Invest       Date:  1973-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.